The Labs Your Doctor Didn't Run (Pre-Protocol Bloodwork Blueprint)

Your doctor checks one number and calls it a day. That number is total testosterone, and if it lands somewhere between 264 and 916 ng/dL, the harmonized reference range built from over 9,000 men, you are told you are fine.

But "in range" is not a diagnosis. It is the absence of an obvious flag, and those are very different things.

To understand why that single number leaves so much on the table, you need to understand how the testosterone system actually works from top to bottom, because the system has multiple points where it can break, and each one has a different fix.

The signal starts in the brain. The hypothalamus releases a hormone that tells the pituitary gland to fire two hormones called LH and FSH, which are the actual chemical messengers that travel through the bloodstream and tell the testes to produce testosterone. The testes respond, testosterone rises, the brain detects the rise and dials back the signal. That is the loop. And the loop can fail at the brain, at the pituitary, or at the testes themselves.

Here is why that matters practically. If your total testosterone is low and your LH and FSH are also low, the problem is upstream, meaning the brain is not sending the signal, and that is called secondary hypogonadism. If your total testosterone is low but your LH and FSH are high, the brain is screaming and the testes are not responding, and that is called primary hypogonadism. These two conditions have completely different causes and completely different treatment paths, and you cannot tell them apart without LH and FSH. The Endocrine Society guideline says this explicitly: measuring LH and FSH is how you distinguish the two, and the American Urological Association recommends LH in all men with low testosterone.

Total testosterone alone tells you nothing about which diagnosis you have.

Now add one more layer. Even when total testosterone looks normal, a protein called SHBG, which stands for sex hormone binding globulin and which acts essentially as a carrier that locks testosterone away from your cells, can make that number misleading. Testosterone bound to SHBG cannot enter a cell. Only what is called free testosterone, the fraction floating unbound in the bloodstream, can actually do anything at the tissue level.

This is why a man with total testosterone at 600 ng/dL can have lower usable testosterone than a man sitting at 400. If the first man has high SHBG, a large fraction of that 600 is locked up and biologically inert. The second man with lower SHBG has more of his 400 actually available to his cells. You would never catch this without measuring SHBG and calculating or directly measuring free testosterone.

Estradiol, prolactin, progesterone, DHEA sulfate, and cortisol round out the hormonal picture. Estradiol is worth a specific note here: measuring it accurately in men requires a method called LC-MS/MS, which is a more precise mass spectrometry technique, because the standard immunoassay tests designed for women's estrogen levels are not sensitive enough to be reliable in the lower range where men operate. If a lab runs the wrong test, the estradiol number can be meaningless.

Move to metabolic health and the same principle applies. A standard panel gives you fasting glucose and maybe hemoglobin A1c, and if both look normal, insulin resistance is not flagged. But insulin resistance can be fully underway while blood glucose still reads normal, because the pancreas is compensating by secreting more and more insulin to hold glucose in range. The glucose number looks fine because the system is working overtime to make it look fine. Fasting insulin catches this, because elevated insulin with normal glucose is the early signature of a system under strain.

Hemoglobin A1c adds the time dimension, showing the average blood sugar picture over roughly three months rather than a single snapshot moment.

On the cardiovascular side, a standard lipid panel gives you total cholesterol, LDL, HDL, and triglycerides. Those numbers describe the amount of cholesterol in the blood. What they do not tell you is particle count, which is actually what drives plaque buildup in arterial walls. A measurement called apolipoprotein B gives you that particle count directly, and it is a stronger predictor of cardiovascular events than LDL alone. High sensitivity C-reactive protein tells you whether there is active low grade inflammation in the cardiovascular system, which is itself an independent risk factor for events.

These two markers tell you what is actually happening. The standard lipid panel tells you what is present.

Safety markers complete the picture. Hematocrit matters here because testosterone stimulates something called erythropoiesis, which is the production of red blood cells, and as hematocrit rises, blood viscosity rises with it. A 2022 study found that men on testosterone therapy with hematocrit at or above 52 percent had a 35 percent higher risk of major cardiovascular events and venous thromboembolism compared to those below that threshold. That is an odds ratio of 1.35, and it is the reason hematocrit is monitored on protocol, not just checked once.

IGF-1 serves a different purpose. If someone later adds growth hormone peptides to a protocol, IGF-1 is the marker that tells you whether it is working. Without a baseline, you are flying blind.

A full thyroid panel, TSH plus free T3 and free T4, matters because thyroid function is woven into energy, mood, metabolism, and testosterone metabolism itself, and TSH alone can look normal while free T3 is low enough to explain every symptom someone came in with. PSA establishes a pre-protocol baseline so any future changes are interpretable.

The pattern across all of these markers is the same. A single number in isolation tells you whether something is grossly abnormal. A complete panel tells you how the system is running, where the friction is, and which direction to move.

Protocols designed without this information are not personalized. They are guesses dressed up in medical language. And the baseline you establish before you start anything is the only reference point you will ever have for measuring whether what you are doing is actually working.

That is the whole point of running the panel before anything else.

---

References

1. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism. JCEM. 2018 — Endocrine Society guideline: diagnosis requires two fasting morning total T measurements, distinguish primary vs secondary via LH/FSH
2. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency. AUA Guideline. J Urology. 2018 — Total T below 300 ng/dL threshold, recommend LH in all men with low T
3. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels. JCEM. 2017 — 9,054 men, harmonized range 264-916 ng/dL
4. Ory J et al. Secondary Polycythemia in Men Receiving Testosterone Therapy. J Urology. 2022 — Hematocrit >=52% on TRT = 35% higher MACE/VTE risk (OR 1.35)
5. Rosner W et al. Toward Excellence in Testosterone Testing. JCEM. 2013 — Sensitive LC-MS/MS required for accurate male estradiol

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness